Literature DB >> 18032477

Saccharomyces boulardii interferes with Shigella pathogenesis by postinvasion signaling events.

Karen L Mumy1, Xinhua Chen, Ciarán P Kelly, Beth A McCormick.   

Abstract

Saccharomyces boulardii is gaining in popularity as a treatment for a variety of diarrheal diseases as well as inflammatory bowel disease. This study was designed to examine the effect of this yeast on infection by Shigella flexneri, a highly infectious and human host-adapted enteric pathogen. We investigated key interactions between the bacteria and host cells in the presence of the yeast in addition to a number of host responses including proinflammatory events and markers. Although the presence of the yeast during infection did not alter the number of bacteria that was able to attach or invade human colon cancer-derived T-84 cells, it did positively impact the tight junction protein zonula occluden-2 and significantly increase the barrier integrity of model epithelia. The yeast also decreased ERK, JNK, and NF-kappaB activation in response to S. flexneri, events likely responsible for the observed reductions in IL-8 secretion and the transepithelial migration of polymorphonuclear leukocytes across T-84 monolayers. These results, suggesting that the yeast allowed for a dampened inflammatory response, were confirmed in vivo utilizing a highly relevant model of human fetal colonic tissue transplanted into scid mice. Furthermore, a cell-free S. boulardii culture supernatant was also capable of reducing IL-8 secretion by infected T-84 cells. These data suggest that although the use of S. boulardii during infection with S. flexneri may alleviate symptoms associated with the inflammatory response of the host, it would not prevent infection.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 18032477      PMCID: PMC3212754          DOI: 10.1152/ajpgi.00391.2007

Source DB:  PubMed          Journal:  Am J Physiol Gastrointest Liver Physiol        ISSN: 0193-1857            Impact factor:   4.052


  52 in total

Review 1.  Experimental effects of Saccharomyces boulardii on diarrheal pathogens.

Authors:  Dorota Czerucka; Patrick Rampal
Journal:  Microbes Infect       Date:  2002-06       Impact factor: 2.700

2.  Saccharomyces boulardii preserves the barrier function and modulates the signal transduction pathway induced in enteropathogenic Escherichia coli-infected T84 cells.

Authors:  D Czerucka; S Dahan; B Mograbi; B Rossi; P Rampal
Journal:  Infect Immun       Date:  2000-10       Impact factor: 3.441

3.  Apical secretion of a pathogen-elicited epithelial chemoattractant activity in response to surface colonization of intestinal epithelia by Salmonella typhimurium.

Authors:  B A McCormick; C A Parkos; S P Colgan; D K Carnes; J L Madara
Journal:  J Immunol       Date:  1998-01-01       Impact factor: 5.422

4.  Invasive Shigella flexneri activates NF-kappa B through a lipopolysaccharide-dependent innate intracellular response and leads to IL-8 expression in epithelial cells.

Authors:  D J Philpott; S Yamaoka; A Israël; P J Sansonetti
Journal:  J Immunol       Date:  2000-07-15       Impact factor: 5.422

5.  CARD4/Nod1 mediates NF-kappaB and JNK activation by invasive Shigella flexneri.

Authors:  S E Girardin; R Tournebize; M Mavris; A L Page; X Li; G R Stark; J Bertin; P S DiStefano; M Yaniv; P J Sansonetti; D J Philpott
Journal:  EMBO Rep       Date:  2001-07-19       Impact factor: 8.807

6.  Shigella infection in a SCID mouse-human intestinal xenograft model: role for neutrophils in containing bacterial dissemination in human intestine.

Authors:  Z Zhang; L Jin; G Champion; K B Seydel; S L Stanley
Journal:  Infect Immun       Date:  2001-05       Impact factor: 3.441

7.  Cadaverine prevents the escape of Shigella flexneri from the phagolysosome: a connection between bacterial dissemination and neutrophil transepithelial signaling.

Authors:  I M Fernandez; M Silva; R Schuch; W A Walker; A M Siber; A T Maurelli; B A McCormick
Journal:  J Infect Dis       Date:  2001-08-24       Impact factor: 5.226

8.  Shigella flexneri Interactions with the Basolateral Membrane Domain of Polarized Model Intestinal Epithelium: Role of Lipopolysaccharide in Cell Invasion and in Activation of the Mitogen-Activated Protein Kinase ERK.

Authors:  Henrik Köhler; Sonia P Rodrigues; Beth A McCormick
Journal:  Infect Immun       Date:  2002-03       Impact factor: 3.441

9.  Saccharomyces boulardii interferes with enterohemorrhagic Escherichia coli-induced signaling pathways in T84 cells.

Authors:  Stephanie Dahan; Guillaume Dalmasso; Veronique Imbert; Jean-Francois Peyron; Patrick Rampal; Dorota Czerucka
Journal:  Infect Immun       Date:  2003-02       Impact factor: 3.441

10.  Shigella flexneri regulates tight junction-associated proteins in human intestinal epithelial cells.

Authors:  Takanori Sakaguchi; Henrik Köhler; Xiubin Gu; Beth A McCormick; Hans-Christian Reinecker
Journal:  Cell Microbiol       Date:  2002-06       Impact factor: 3.715

View more
  25 in total

Review 1.  Effects of dietary components on intestinal permeability in health and disease.

Authors:  Katayoun Khoshbin; Michael Camilleri
Journal:  Am J Physiol Gastrointest Liver Physiol       Date:  2020-09-09       Impact factor: 4.052

Review 2.  Gleaning Insights from Fecal Microbiota Transplantation and Probiotic Studies for the Rational Design of Combination Microbial Therapies.

Authors:  Lauren E Hudson; Sarah E Anderson; Anita H Corbett; Tracey J Lamb
Journal:  Clin Microbiol Rev       Date:  2017-01       Impact factor: 26.132

3.  Interaction of Saccharomyces boulardii with Salmonella enterica serovar Typhimurium protects mice and modifies T84 cell response to the infection.

Authors:  Flaviano S Martins; Guillaume Dalmasso; Rosa M E Arantes; Anne Doye; Emmanuel Lemichez; Patricia Lagadec; Veronique Imbert; Jean-François Peyron; Patrick Rampal; Jacques R Nicoli; Dorota Czerucka
Journal:  PLoS One       Date:  2010-01-27       Impact factor: 3.240

Review 4.  Review article: anti-inflammatory mechanisms of action of Saccharomyces boulardii.

Authors:  C Pothoulakis
Journal:  Aliment Pharmacol Ther       Date:  2008-07-23       Impact factor: 8.171

Review 5.  Saccharomyces boulardii in childhood.

Authors:  Yvan Vandenplas; Oscar Brunser; Hania Szajewska
Journal:  Eur J Pediatr       Date:  2008-12-19       Impact factor: 3.183

6.  Saccharomyces boulardii improves intestinal epithelial cell restitution by inhibiting αvβ5 integrin activation state.

Authors:  Alexandra Canonici; Emilie Pellegrino; Carole Siret; Chloé Terciolo; Dorota Czerucka; Sonia Bastonero; Jacques Marvaldi; Dominique Lombardo; Véronique Rigot; Frédéric André
Journal:  PLoS One       Date:  2012-09-20       Impact factor: 3.240

7.  Efficacy and safety of the probiotic Saccharomyces boulardii for the prevention and therapy of gastrointestinal disorders.

Authors:  Theodoros Kelesidis; Charalabos Pothoulakis
Journal:  Therap Adv Gastroenterol       Date:  2012-03       Impact factor: 4.802

8.  Saccharomyces boulardii improves intestinal cell restitution through activation of the α2β1 integrin collagen receptor.

Authors:  Alexandra Canonici; Carole Siret; Emilie Pellegrino; Rodolphe Pontier-Bres; Laurent Pouyet; Marie Pierre Montero; Carole Colin; Dorota Czerucka; Véronique Rigot; Frédéric André
Journal:  PLoS One       Date:  2011-03-31       Impact factor: 3.240

9.  Probiotic yeast inhibits VEGFR signaling and angiogenesis in intestinal inflammation.

Authors:  Xinhua Chen; Guoxun Yang; Joo-Hye Song; Hua Xu; Dan Li; Jeffrey Goldsmith; Huiyan Zeng; Patricia A Parsons-Wingerter; Hans-Christian Reinecker; Ciaran P Kelly
Journal:  PLoS One       Date:  2013-05-13       Impact factor: 3.240

10.  Modulation of PPAR-γ by Nutraceutics as Complementary Treatment for Obesity-Related Disorders and Inflammatory Diseases.

Authors:  D Ortuño Sahagún; A L Márquez-Aguirre; S Quintero-Fabián; R I López-Roa; A E Rojas-Mayorquín
Journal:  PPAR Res       Date:  2012-11-28       Impact factor: 4.964

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.